# Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT03955146** · PHASE3 · TERMINATED · sponsor: **Kyntra Bio** · enrollment: 393 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Pamrevlumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03955146
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-18
- **Primary completion:** 2023-03-20
- **Final completion:** 2023-08-28
- **Target enrollment:** 393 (ACTUAL)
- **Why stopped:** Study did not meet its primary endpoint.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03955146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03955146, "Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03955146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*